Therefore, the 2016 WHO revision recognized AML with biallelic mutation of CEBPA as a distinct entity of AML, and AML with germline CEBPA mutation was placed under a separate subcategory of myeloid neoplasms with germline predisposition [34]. This evidence concerns the gene CEBPA and myeloid neoplasm.